Targeting the potential of PSMA
Telix’s prostate cancer portfolio targets PSMA (prostate-specific membrane antigen) – a protein that is overexpressed on the surface of prostate cancer cells and is low or absent on most normal healthy cells. PSMA has become a major breakthrough in the staging, treatment and management of prostate cancer, and the growing field of nuclear medicine.
High rates of screening in developed countries mean many men are diagnosed and treated early before their disease has spread. These men receive local therapy, either prostatectomy or EBRT, and may be cured of their disease. However, approximately 15% of patients develop advanced forms of the disease that can spread to other parts of the body. This is known as metastatic prostate cancer.
Imaging with targeted radiation can identify prostate cancer wherever it is in the body and help guide patient treatment.
Prostate cancer worldwide
1.4 million
estimated global incidence of prostate cancer in 2022
375,000+
men died from prostate cancer globally in 2021
34%
increase in prostate cancer diagnoses in Australia during the past 12 months
99%
5-year survival rate for men diagnosed with early-stage prostate cancer in the United States
Tagawa ST, Vallabhajosula S, Christos PJ, et al. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer. Cancer. 2019;125(15):2561-2569. doi:10.1002/cncr.32072